Correction

Hematologic diseases Pharmacology
Volume 182 - Issue 1

Correction: Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Haemostasis and Thrombosis

Authors:  Ross I Baker, Paul B Coughlin, Hatem H Salem, Alex S Gallus, Paul L Harper and Erica M Wood

Med J Aust 2005; 182 (1): 48. || doi: 10.5694/j.1326-5377.2005.tb06567.x
Published online: 3 January 2005
Download PDF (260 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

Re: “Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Haemostasis and Thrombosis”, by Ross I Baker, Paul B Coughlin, Alex S Gallus, et al on behalf of the Warfarin Reversal Consensus Group (Med J Aust 2004; 181: 492-497). In Box 5, an asterisk in the Box title should have attributed Prothombinex-HT to CSL Limited, the manufacturer of all plasma-derived therapeutic products fractionated from Australian plasma.

The error only appeared in the printed edition. The html and pdf versions of the article published in the eMJA were correct on publication.

Authors

  • Ross I Baker PhD, FRACP1
  • Paul B Coughlin PhD, FRACP, FRCPA2
  • Hatem H Salem MD, FRACP, FRCPA3
  • Alex S Gallus FRACP, FRCPA, FRCP4
  • Paul L Harper MD, FRACP, FRCPA5
  • Erica M Wood FRACP, FRCPA6
  • 1. Thrombosis and Haemophilia Service, Royal Perth Hospital, Perth, WA.
  • 2. Monash University, Box Hill Hospital, Box Hill, VIC.
  • 3. SouthPath, Flinders Medical Centre, Bedford Park, SA.
  • 4. Auckland City Hospital, Auckland, New Zealand.
  • 5. Australian Red Cross Blood Service, Southbank, VIC.
View this article on Wiley Online Library

More like this

View more